<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01165671</url>
  </required_header>
  <id_info>
    <org_study_id>CLEOPATRA</org_study_id>
    <secondary_id>2009-014668-21</secondary_id>
    <secondary_id>ISRCTN37428883</secondary_id>
    <nct_id>NCT01165671</nct_id>
  </id_info>
  <brief_title>Carbon Ion Radiotherapy for Primary Glioblastoma</brief_title>
  <acronym>CLEOPATRA</acronym>
  <official_title>Randomized Phase II Study Evaluating a Carbon Ion Boost Applied After Combined Radiochemotherapy With Temozolomide Versus a Proton Boost After Radiochemotherapy With Temozolomide in Patients With Primary Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment standard for patients with primary glioblastoma (GBM) is combined radiochemotherapy&#xD;
      with temozolomide (TMZ). Radiation is delivered up to a total dose of 60 Gy using photons.&#xD;
      Using this treatment regimen, overall survival could be extended significantly however,&#xD;
      median overall survival is still only about 15 months.&#xD;
&#xD;
      Carbon ions offer physical and biological advantages. Due to their inverted dose profile and&#xD;
      the high local dose deposition within the Bragg peak precise dose application and sparing of&#xD;
      normal tissue is possible. Moreover, in comparison to photons, carbon ions offer an increase&#xD;
      relative biological effectiveness (RBE), which can be calculated between 2 and 5 depending on&#xD;
      the GBM cell line as well as the endpoint analyzed. Protons, however, offer an RBE which is&#xD;
      comparable to photons.&#xD;
&#xD;
      First Japanese Data on the evaluation of carbon ion radiation therapy showed promising&#xD;
      results in a small and heterogeneous patient collective.&#xD;
&#xD;
      In the current Phase II-CLEOPATRA-Study a carbon ion boost will be compared to a proton boost&#xD;
      applied to the macroscopic tumor after surgery at primary diagnosis in patients with GBM&#xD;
      applied after standard radiochemotherapy with TMZ up to 50 Gy. In the experimental arm, a&#xD;
      carbon ion boost will be applied to the macroscopic tumor up to a total dose of 18 Gy E in 6&#xD;
      fractions at a single dose of 3 Gy E. In the standard arm, a proton boost will be applied up&#xD;
      to a total dose 10 Gy E in 5 single fractions of 2 Gy E.&#xD;
&#xD;
      Primary endpoint is overall survival, secondary objectives are progression-free survival,&#xD;
      toxicity and safety.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design&#xD;
&#xD;
      The purpose of the trial is to compare a carbon ion boost to a proton boost delivered to the&#xD;
      macroscopic tumor in combination with combined radiochemotherapy with TMZ in patients with&#xD;
      primary GBM.&#xD;
&#xD;
      The aim of the study is to compare overall survival as a primary endpoint, and progression&#xD;
      free survival, toxicity and safety as secondary endpoints.&#xD;
&#xD;
      Focus of the analysis is to evaluate the change in overall survival and local control by&#xD;
      carbon ion radiotherapy. Therefore, the aim of the trial is to evaluate the improvement in&#xD;
      outcome due to effect of the altered biology of carbon ions on GBM. Chemotherapy with TMZ is&#xD;
      considered standard treatment and is administered continuously as it would be applied in&#xD;
      standard patient care outside any trial.&#xD;
&#xD;
      Trial Design The trial will be performed as a single-center two-armed randomized Phase II&#xD;
      study.&#xD;
&#xD;
      Patients fulfilling the inclusion criteria will be randomized into two arms:&#xD;
&#xD;
      Arm A - Experimental Arm Carbon Ion Radiation Therapy as a Boost to the macroscopic tumor&#xD;
      Total Dose 18 Gy E, 6 fractions, 3 Gy E single dose&#xD;
&#xD;
      Arm B - Standard Arm Proton Radiation Therapy as a Boost to the macroscopic tumor Total Dose&#xD;
      10 Gy E, 5 fractions, 2 Gy E single dose&#xD;
&#xD;
      Standard chemotherapy with TMZ will be continued during the experimental and standard arm in&#xD;
      conventional dosing of 75 mg/m2 per day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2010</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>within 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>within 12 months</time_frame>
    <description>CTCAC 5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Primary Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carbon Ion Radiotherapy to the Macroscopic Tumor 6 x 3 Gy E up to 18 Gy E</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Proton Radiotherapy to the Macroscopic Tumor 5 x 2 Gy E up to 10 Gy E (Standard dose) applied after 48-52 Gy photon radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Carbon Ion Radiotherapy</intervention_name>
    <description>Carbon ion Radiotherapy up to 18 Gy E in 3 Gy E fractions to the macroscopic tumor</description>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton Radiotherapy</intervention_name>
    <description>Proton Radiotherapy up to 10 Gy E in 2 Gy E fractions to the macroscopic tumor</description>
    <arm_group_label>Standard Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically confirmed unifocal, supratentorial primary glioblastoma&#xD;
&#xD;
          -  macroscopic tumor after biopsy or subtotal resection&#xD;
&#xD;
          -  indication for combined radiochemotherapy with temozolomide&#xD;
&#xD;
          -  prior photon irradiation of 48-52 Gy to the T2-hyperintense area, resection cavity,&#xD;
             areas of contrast enhancement adding 2-3cm safety margin in combination with standard&#xD;
             temozolomide&#xD;
&#xD;
          -  registration prior to photon RT or within photon RT allowing the beginning of particle&#xD;
             therapy ≤ 4 days after completion of photon irradiation&#xD;
&#xD;
          -  beginning of study treatment (proton or carbon ion RT) no later than 12 weeks after&#xD;
             primary diagnosis&#xD;
&#xD;
          -  age ≥ 18 years&#xD;
&#xD;
          -  Karnofsky Performance Score ≥ 60&#xD;
&#xD;
          -  adequate contraception.&#xD;
&#xD;
          -  Ability of subject to understand character and individual consequences of the clinical&#xD;
             trial&#xD;
&#xD;
          -  Written informed consent (must be available before enrolment in the trial)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  refusal of the patients to take part in the study&#xD;
&#xD;
          -  previous radiotherapy of the brain or chemotherapy with DTIC or TMZ other than during&#xD;
             the radiochemotherapy stated in the inclusion criteria&#xD;
&#xD;
          -  more than 52 Gy applied via photon-RT prior to particle therapy&#xD;
&#xD;
          -  time interval of &gt; 12 weeks after primary diagnosis (neurosurgical intervention) and&#xD;
             beginning of study treatment (proton or carbon ion RT)&#xD;
&#xD;
          -  Patients who have not yet recovered from acute toxicities of prior therapies&#xD;
&#xD;
          -  Clinically active kidney, liver or cardiac disease&#xD;
&#xD;
          -  Known carcinoma &lt; 5 years ago (excluding Carcinoma in situ of the cervix, basal cell&#xD;
             carcinoma, squamous cell carcinoma of the skin) requiring immediate treatment&#xD;
             interfering with study therapy&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Participation in another clinical study or observation period of competing trials,&#xD;
             respectively.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital of Heidelberg, Department of Radiation Oncology</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.klinikum.uni-heidelberg.de/ro</url>
    <description>Homepage Department of Radiation Oncology</description>
  </link>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>July 13, 2010</study_first_submitted>
  <study_first_submitted_qc>July 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2010</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Juergen Debus</investigator_full_name>
    <investigator_title>Prof. Dr. Dr. Jürgen Debus</investigator_title>
  </responsible_party>
  <keyword>Primary Glioblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

